MAZE THERAPEUTICS INC (MAZE) Fundamental Analysis & Valuation

NASDAQ:MAZE • US5787841007

Current stock price

26.58 USD
+0.9 (+3.5%)
At close:
26.58 USD
0 (0%)
After Hours:

This MAZE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MAZE Profitability Analysis

1.1 Basic Checks

  • MAZE had negative earnings in the past year.
  • MAZE had a negative operating cash flow in the past year.
MAZE Yearly Net Income VS EBIT VS OCF VS FCFMAZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • MAZE's Return On Assets of -33.02% is in line compared to the rest of the industry. MAZE outperforms 48.69% of its industry peers.
  • With a decent Return On Equity value of -36.94%, MAZE is doing good in the industry, outperforming 60.73% of the companies in the same industry.
Industry RankSector Rank
ROA -33.02%
ROE -36.94%
ROIC N/A
ROA(3y)-57.34%
ROA(5y)N/A
ROE(3y)-344.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAZE Yearly ROA, ROE, ROICMAZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • MAZE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAZE Yearly Profit, Operating, Gross MarginsMAZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MAZE Health Analysis

2.1 Basic Checks

  • MAZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MAZE has been increased compared to 1 year ago.
  • MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MAZE Yearly Shares OutstandingMAZE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
MAZE Yearly Total Debt VS Total AssetsMAZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MAZE has an Altman-Z score of 16.24. This indicates that MAZE is financially healthy and has little risk of bankruptcy at the moment.
  • MAZE has a Altman-Z score of 16.24. This is amongst the best in the industry. MAZE outperforms 86.91% of its industry peers.
  • There is no outstanding debt for MAZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.24
ROIC/WACCN/A
WACC9.69%
MAZE Yearly LT Debt VS Equity VS FCFMAZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 15.50 indicates that MAZE has no problem at all paying its short term obligations.
  • MAZE has a Current ratio of 15.50. This is amongst the best in the industry. MAZE outperforms 89.53% of its industry peers.
  • A Quick Ratio of 15.50 indicates that MAZE has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 15.50, MAZE belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.5
Quick Ratio 15.5
MAZE Yearly Current Assets VS Current LiabilitesMAZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MAZE Growth Analysis

3.1 Past

  • MAZE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -4021.59%.
  • Looking at the last year, MAZE shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-4021.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.45%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MAZE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.22% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.09%
EPS Next 2Y-0.14%
EPS Next 3Y-3.05%
EPS Next 5Y6.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAZE Yearly Revenue VS EstimatesMAZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
MAZE Yearly EPS VS EstimatesMAZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. MAZE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MAZE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MAZE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAZE Price Earnings VS Forward Price EarningsMAZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MAZE Per share dataMAZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as MAZE's earnings are expected to decrease with -3.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.14%
EPS Next 3Y-3.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MAZE Dividend Analysis

5.1 Amount

  • No dividends for MAZE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAZE Fundamentals: All Metrics, Ratios and Statistics

MAZE THERAPEUTICS INC

NASDAQ:MAZE (4/30/2026, 8:01:14 PM)

After market: 26.58 0 (0%)

26.58

+0.9 (+3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.84
Industry Growth15.53
Earnings (Last)03-25
Earnings (Next)05-20
Inst Owners91.67%
Inst Owner Change-0.05%
Ins Owners1.82%
Ins Owner Change-31.55%
Market Cap1.32B
Revenue(TTM)N/A
Net Income(TTM)-131.12M
Analysts86.67
Price Target66.81 (151.35%)
Short Float %8.7%
Short Ratio4.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.69%
Min EPS beat(2)8.68%
Max EPS beat(2)10.7%
EPS beat(4)3
Avg EPS beat(4)-4.62%
Min EPS beat(4)-49.66%
Max EPS beat(4)11.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.38%
PT rev (3m)42.01%
EPS NQ rev (1m)28.88%
EPS NQ rev (3m)28.99%
EPS NY rev (1m)10.3%
EPS NY rev (3m)10.58%
Revenue NQ rev (1m)2995.1%
Revenue NQ rev (3m)2376.08%
Revenue NY rev (1m)757.35%
Revenue NY rev (3m)757.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS7.14
TBVpS7.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -33.02%
ROE -36.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.34%
ROA(5y)N/A
ROE(3y)-344.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.5
Quick Ratio 15.5
Altman-Z 16.24
F-Score3
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)26.21%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4021.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.45%
EPS Next Y11.09%
EPS Next 2Y-0.14%
EPS Next 3Y-3.05%
EPS Next 5Y6.22%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-348.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.48%
EBIT Next 3Y-12.53%
EBIT Next 5YN/A
FCF growth 1Y-250.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-247.38%
OCF growth 3YN/A
OCF growth 5YN/A

MAZE THERAPEUTICS INC / MAZE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MAZE.


What is the valuation status of MAZE THERAPEUTICS INC (MAZE) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAZE THERAPEUTICS INC (MAZE). This can be considered as Overvalued.


What is the profitability of MAZE stock?

MAZE THERAPEUTICS INC (MAZE) has a profitability rating of 1 / 10.


What is the financial health of MAZE THERAPEUTICS INC (MAZE) stock?

The financial health rating of MAZE THERAPEUTICS INC (MAZE) is 8 / 10.